文献速递胸部肿瘤

术前循环肿瘤DNA检测与亚肺叶切除与I期非小细胞肺癌复发风险的关联

Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2025-01-13

该前瞻性研究纳入544例临床I期、实性为主(CTR>0.5)的非小细胞肺癌患者,术前采用基于甲基化的肿瘤无关循环肿瘤DNA检测。术前ctDNA阳性患者中,亚肺叶切除与复发风险升高相关(校正HR 2.25,95%CI 1.12-4.54,p=0.024);而ctDNA阴性患者中未见显著增加(校正HR 1.01,p=0.98)。

要点

  • 术前ctDNA在188例(35%)患者中检出。
  • ctDNA阳性者亚肺叶切除与复发风险升高相关(校正HR 2.25,95%CI 1.12-4.54)。
  • ctDNA阴性者亚肺叶切除未显著增加复发风险(校正HR 1.01,p=0.98)。

核心结论

  • 术前肿瘤无关ctDNA分析有望识别出可能无法通过亚肺叶切除充分治疗的侵袭性肿瘤患者,有助于个体化治疗策略并可能改善早期NSCLC患者结局。

研究设计与样本

  • 前瞻性招募2014年3月至2020年12月期间临床I期、实性为主(CTR>0.5)的NSCLC患者,共纳入544例(178例女性[33%],中位年龄66岁[IQR 60-71])。
  • 术前血浆样本采用基于甲基化的肿瘤无关游离DNA检测进行分析。
  • 根据术前ctDNA状态评估亚肺叶切除与肺叶切除对无复发生存期(RFS)的影响,并分析术前ctDNA检出与临床病理因素的关联。

主要发现

  • 术前ctDNA在188例(35%)患者中检出。
  • 在无术前ctDNA的患者中,亚肺叶切除未显著增加复发风险(校正HR 1.01,p=0.98)。
  • 在ctDNA阳性患者中,亚肺叶切除与复发风险升高相关(校正HR 2.25,95%CI 1.12-4.54,p=0.024)。
  • 术前ctDNA阳性患者有更高的淋巴结升级率(OR 3.58,p<0.001),并且病理分级更高(p=0.021)、神经周围侵犯(p<0.001)和淋巴血管侵犯(p<0.001)发生率更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sublobar resection is increasingly recognized as an effective treatment for early-stage NSCLC. However, no studies to date have investigated the potential role of preoperative ctDNA detection in guiding surgical decisions, such as opting for sublobar resection, in stage I NSCLC. METHODS: Patients with solid-dominant (CTR>0.5), clinical stage I NSCLC were prospectively recruited between March 2014 and December 2020. Pre-surgical plasma samples were analyzed using a tumor-naïve, methylation-based cell-free DNA assay. The impact of sublobar resection versus lobectomy on recurrence-free survival (RFS) was assessed according to pre-surgical ctDNA status. Associations between pre-surgical ctDNA detection and clinicopathologic factors were also investigated. RESULTS: The analysis included 544 patients (178 women [33 %]; median age 66 [IQR, 60-71] years). Pre-surgical ctDNA was detected in 188 (35 %) patients. In patients without presurgical ctDNA, sublobar resection did not significantly increase the risk of relapse (adjusted HR, 1.01, p = 0.98). However, among ctDNA-positive patients, sublobar resection was associated with an increased risk of relapse (adjusted HR, 2.25; 95 % CI, 1.12-4.54; p = 0.024). Patients with presurgical ctDNA had higher rates of nodal upstaging (OR, 3.58; p < 0.001) and exhibited higher pathologic grade (p = 0.021), perineural invasion (p < 0.001), and lymphovascular invasion (p < 0.001). CONCLUSIONS: Pre-surgical tumor-naïve ctDNA analysis holds promise in identifying patients with aggressive tumors that may not be sufficiently managed with sublobar resection. This approach can help personalize treatment strategies, potentially improving outcomes for patients with early-stage NSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hong TH, Hwang S, Abbosh C, et al. Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer. Eur J Cancer. 2025. PMID: 39826198. doi:10.1016/j.ejca.2025.115237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。